Black Diamond Therapeutics Stock Today
| BDTX Stock | USD 3.24 0.14 4.14% |
Performance0 of 100
| Odds Of DistressOver 59
|
Black Diamond is trading at 3.24 as of the 13th of November 2024; that is 4.14 percent decrease since the beginning of the trading day. The stock's open price was 3.38. Black Diamond has over 59 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for Black Diamond Therapeutics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 18th of January 2024 and ending today, the 13th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of January 2020 | Category Healthcare | Classification Health Care |
Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. The company has 56.59 M outstanding shares of which 6.33 M shares are currently shorted by private and institutional investors with about 3.06 trading days to cover. More on Black Diamond Therapeutics
Moving together with Black Stock
Moving against Black Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Black Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsBlack Diamond can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Black Diamond's financial leverage. It provides some insight into what part of Black Diamond's total assets is financed by creditors.
| |||||
Black Diamond Therapeutics (BDTX) is traded on NASDAQ Exchange in USA. It is located in One Main Street, Cambridge, MA, United States, 02142 and employs 54 people. Black Diamond is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 191.26 M. Black Diamond Therap conducts business under Biotechnology sector and is part of Health Care industry. The entity has 56.59 M outstanding shares of which 6.33 M shares are currently shorted by private and institutional investors with about 3.06 trading days to cover.
Black Diamond Therapeutics currently holds about 160.89 M in cash with (66.72 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.43, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Black Diamond Probability Of Bankruptcy
Ownership AllocationBlack Diamond holds a total of 56.59 Million outstanding shares. The majority of Black Diamond Therapeutics outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in Black Diamond Therap to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Black Diamond. Please pay attention to any change in the institutional holdings of Black Diamond Therapeutics as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check Black Ownership Details
Black Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| T. Rowe Price Associates, Inc. | 2024-06-30 | 813.1 K | |
| Amvescap Plc. | 2024-06-30 | 712.4 K | |
| Kennedy Capital Management Inc | 2024-06-30 | 703.3 K | |
| State Street Corp | 2024-06-30 | 690.4 K | |
| Stempoint Capital Lp | 2024-06-30 | 674.2 K | |
| Affinity Asset Advisors, Llc | 2024-06-30 | 650 K | |
| Driehaus Capital Management Llc | 2024-06-30 | 605.9 K | |
| Exoduspoint Capital Management, Lp | 2024-06-30 | 588.6 K | |
| Boxer Capital Llc | 2024-06-30 | 506 K | |
| T. Rowe Price Investment Management,inc. | 2024-06-30 | 10.7 M | |
| Bellevue Group Ag | 2024-06-30 | 8.5 M |
Black Diamond Historical Income Statement
Black Stock Against Markets
Black Diamond Corporate Management
| Melanie Morrison | Sr Operations | Profile | |
| Fang PharmD | Principal CFO | Profile | |
| Christopher Roberts | Advisor | Profile | |
| Elizabeth Montgomery | Chief Officer | Profile | |
| TaiAn Lin | VP Biology | Profile | |
| JD Esq | COO Counsel | Profile | |
| Elizabeth Buck | CoFounder Officer | Profile |
Additional Tools for Black Stock Analysis
When running Black Diamond's price analysis, check to measure Black Diamond's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Black Diamond is operating at the current time. Most of Black Diamond's value examination focuses on studying past and present price action to predict the probability of Black Diamond's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Black Diamond's price. Additionally, you may evaluate how the addition of Black Diamond to your portfolios can decrease your overall portfolio volatility.